Margaret Block
Oncology
7500 Mercy Rd Ste 1300
Omaha, NE 68124
Omaha, NE 68124
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.
Journal: JCO oncology advances
Published: May 18, 2026
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 12, 2025
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Journal: Cancer
Published: August 07, 2023
Reply to T. Shimoi et al and Y. Shimanuki et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 23, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 07, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 10, 2021
Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Journal: JAMA network open
Published: April 20, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026